Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
29.62
-0.21 (-0.70%)
Mar 20, 2026, 3:00 PM CST
SHA:688566 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 847.48 | 694.87 | 903.9 | 1,025 |
Trading Asset Securities | - | 56 | 35 | 90 | 200 |
Cash & Short-Term Investments | 888.72 | 903.48 | 729.87 | 993.9 | 1,225 |
Cash Growth | -1.63% | 23.79% | -26.57% | -18.87% | -4.84% |
Accounts Receivable | - | 300.75 | 369.15 | 216.21 | 146.6 |
Other Receivables | - | 0.05 | 0.03 | 0.02 | - |
Receivables | - | 300.8 | 369.17 | 216.23 | 146.6 |
Inventory | - | 30.7 | 29.51 | 32.66 | 31.83 |
Other Current Assets | - | 69.46 | 2.59 | 13.98 | 2.62 |
Total Current Assets | - | 1,304 | 1,131 | 1,257 | 1,406 |
Property, Plant & Equipment | - | 986.86 | 832.49 | 552.21 | 271.51 |
Long-Term Investments | - | 79.79 | 126.19 | 61.74 | 56.63 |
Other Intangible Assets | - | 56.69 | 58.2 | 59.74 | 61.28 |
Long-Term Deferred Tax Assets | - | 17.93 | 16.13 | 15.59 | 11.72 |
Long-Term Deferred Charges | - | 32.14 | 1.13 | 2.18 | 3.25 |
Other Long-Term Assets | - | 49.69 | 44.38 | 16.34 | 8.21 |
Total Assets | - | 2,528 | 2,210 | 1,965 | 1,819 |
Accounts Payable | - | 97.15 | 91.22 | 101.67 | 69.92 |
Accrued Expenses | - | 45.73 | 86.79 | 53.49 | 35.3 |
Short-Term Debt | - | 20.83 | 9.91 | - | - |
Current Income Taxes Payable | - | 2.01 | 0.19 | 6.09 | 5.19 |
Current Unearned Revenue | - | 0.95 | 1.81 | 3.42 | 1.51 |
Other Current Liabilities | - | 18.53 | 20.39 | 16.69 | 12.14 |
Total Current Liabilities | - | 185.19 | 210.31 | 181.36 | 124.06 |
Long-Term Unearned Revenue | - | 58.59 | 59.04 | 58.85 | 59.7 |
Long-Term Deferred Tax Liabilities | - | 3.25 | 3.25 | 3.4 | - |
Other Long-Term Liabilities | - | 26.64 | 26.64 | 26.64 | 26.64 |
Total Liabilities | - | 273.68 | 299.25 | 270.24 | 210.4 |
Common Stock | - | 199.43 | 189.08 | 186.94 | 186.94 |
Additional Paid-In Capital | - | 1,299 | 1,082 | 1,042 | 1,021 |
Retained Earnings | - | 749.77 | 633.4 | 459.17 | 394.24 |
Total Common Equity | 2,358 | 2,249 | 1,905 | 1,688 | 1,602 |
Minority Interest | - | 5.23 | 5.58 | 5.9 | 6.31 |
Shareholders' Equity | 2,370 | 2,254 | 1,910 | 1,694 | 1,608 |
Total Liabilities & Equity | - | 2,528 | 2,210 | 1,965 | 1,819 |
Total Debt | 22.01 | 20.83 | 9.91 | - | - |
Net Cash (Debt) | 866.71 | 882.65 | 719.96 | 993.9 | 1,225 |
Net Cash Growth | -1.81% | 22.60% | -27.56% | -18.87% | -4.84% |
Net Cash Per Share | 4.36 | 4.55 | 3.84 | 5.33 | 6.50 |
Filing Date Shares Outstanding | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 |
Total Common Shares Outstanding | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 |
Working Capital | - | 1,119 | 920.84 | 1,075 | 1,282 |
Book Value Per Share | 11.82 | 11.28 | 10.07 | 9.03 | 8.57 |
Tangible Book Value | 2,264 | 2,192 | 1,847 | 1,629 | 1,541 |
Tangible Book Value Per Share | 11.35 | 10.99 | 9.77 | 8.71 | 8.24 |
Buildings | - | 142.66 | 142.66 | 142.52 | 142.52 |
Machinery | - | 75.26 | 74.81 | 73.37 | 72.78 |
Construction In Progress | - | 917.62 | 754.62 | 466.36 | 175.48 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.